NCT03240315Active, not recruiting
Personalized Prediction Strategy for Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Establishment of Individualized Prediction System for Acute Exacerbation of Chronic Obstructive Pulmonary Disease Based on Cloud Platform
Source: ClinicalTrials.gov · Last updated 12 Jan 2026
Brief summary (registry, in English)
This is a 3-year longitudinal study designed to establish a personalized prediction and prevention system for acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Data will be prospectively collected from patients with chronic obstructive pulmonary disease (COPD) and healthy control participants, including clinical characteristics, pathophysiological parameters, etiological factors, and immunological information. These data will be analyzed using data mining approaches combined with Internet-based technologies.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 442 (actual)
- First submitted
- 31 Jul 2017
- Start date
- 1 Aug 2016
- Primary completion date
- 30 Sept 2026
- Lead sponsor
- Guangzhou Institute of Respiratory Disease
- Diseases
- COPD
- NCT number
- NCT03240315
What you commit to
- Study type: Observational
- Participants enrolled: 442
- From 1 Aug 2016 to the primary completion date, 30 Sept 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- A COPD subject will not be eligible for inclusion in this study if any of the following criteria apply:
- Known respiratory disorders, or disorders identified at screening/visit 1 (including identification on the first CT scan), other than COPD (e.g.: lung cancer, sarcoidosis, tuberculosis, lung fibrosis, cystic fibrosis)
- Known history of significant inflammatory disease, other than COPD (e.g. rheumatoid arthritis and Lupus)
- Known to be severely alpha-1-antitrypsin deficient
- Has experienced a moderate or severe exacerbation (requiring oral corticosteroid, antibiotics or hospitalisation) within the last 4 weeks
- Having undergone lung surgery (e.g. lung reduction, lung transplant)
- Have cancer or have had cancer in the 5 years prior to study entry
- Having received a blood transfusion in the 4 weeks prior to study start
- Inability to walk
- Taking part in a blinded drug study
- Having therapy with systemic corticosteroids at inclusion.
Who the study is looking for
- Patients was diagnosed as COPD according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines older than 40 years old.
- A signed and dated written informed consent is obtained prior to participation.
- Able to comply with the requirements of the protocol and be available for study visits over 3 years.
Age in the registry: 40 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Guangzhou Institute of Respiratory Health,The First Affiliated Hospital of Guangzhou Medical University Coordinator of this site? Confirm its status | Guangzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.